Brief: Hedgepath Pharmaceuticals, Mayne Pharma Enter Updated Collaboration & Funding Agreements

Inhibitor Therapeutics

17/12/2018 22:11

Dec 17 (Reuters) - HedgePath Pharmaceuticals Inc  HPPI.PK :
    * HEDGEPATH PHARMACEUTICALS AND MAYNE PHARMA ENTER INTO
UPDATED
COLLABORATION AND FUNDING AGREEMENTS
    * UNDER NEW SLA, CO WILL ASSUME CONTROL OF REGULATORY AND
CLINICAL
DEVELOPMENT PROGRAM FOR SUBA-ITRACONAZOLE
    * TO TRANSFER SUBA-ITRACONAZOLE BCCNS CLINICAL PROGRAM TO
MAYNE IN
CONSIDERATION OF UP TO $5 MILLION IN NEW FUNDING FROM MAYNE
    * WILL IMMEDIATELY ASSUME RESPONSIBILITY FOR ALL FUTURE
SUBA-ITRACONAZOLE BCCNS-RELATED EXPENSES
    * WITH NEW FUNDING, CO TO MOVE TOWARDS IND FILING DURING
2019 &
RECRUITMENT TO INITIATE HUMAN TRIALS FOR SUBA-ITRACONAZOLE
PROSTATE
    * CO TO RECEIVE 9% ROYALTY ON FUTURE NET SALES OF
SUBA-ITRACONAZOLE BCCNS IN U.S.

Source text for Eikon:  ID:nPn3CfpkWa 
Further company coverage:  HPPI.PK 

 ((Reuters.Briefs@thomsonreuters.com;))